These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 26551391)
1. Potential therapeutic effects of mTOR inhibition in atherosclerosis. Kurdi A; De Meyer GR; Martinet W Br J Clin Pharmacol; 2016 Nov; 82(5):1267-1279. PubMed ID: 26551391 [TBL] [Abstract][Full Text] [Related]
2. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Martinet W; De Loof H; De Meyer GRY Atherosclerosis; 2014 Apr; 233(2):601-607. PubMed ID: 24534455 [TBL] [Abstract][Full Text] [Related]
3. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751 [TBL] [Abstract][Full Text] [Related]
4. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer. Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814 [TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
6. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852 [TBL] [Abstract][Full Text] [Related]
7. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Montero JC; Chen X; Ocaña A; Pandiella A Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482 [TBL] [Abstract][Full Text] [Related]
8. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship. Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692 [TBL] [Abstract][Full Text] [Related]
9. Small molecules bind human mTOR protein and inhibit mTORC1 specifically. Allen SA; Tomilov A; Cortopassi GA Biochem Pharmacol; 2018 Sep; 155():298-304. PubMed ID: 30028993 [TBL] [Abstract][Full Text] [Related]
10. In vitro antiglioma action of indomethacin is mediated via AMP-activated protein kinase/mTOR complex 1 signalling pathway. Pantovic A; Bosnjak M; Arsikin K; Kosic M; Mandic M; Ristic B; Tosic J; Grujicic D; Isakovic A; Micic N; Trajkovic V; Harhaji-Trajkovic L Int J Biochem Cell Biol; 2017 Feb; 83():84-96. PubMed ID: 27988363 [TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608 [TBL] [Abstract][Full Text] [Related]
12. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756 [TBL] [Abstract][Full Text] [Related]
13. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676 [TBL] [Abstract][Full Text] [Related]
14. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. Herschbein L; Liesveld JL Blood Rev; 2018 May; 32(3):235-248. PubMed ID: 29276026 [TBL] [Abstract][Full Text] [Related]
15. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075 [TBL] [Abstract][Full Text] [Related]
16. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786 [TBL] [Abstract][Full Text] [Related]
17. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival. Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293 [TBL] [Abstract][Full Text] [Related]